Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Multicenter Evaluation of the Hemostatic Activity of Emicizumab in Patients with Severe Hemophilia a Using Thrombin Generation Assay

Laurie Josset, Maissaa Janbain, Annaelle De Wreede, Christophe Nougier, Stephanie Desage, Anne Lienhart, Xavier Delavenne, Yesim G. Dargaud

Blood (2023) 142 (Supplement 1): 5459.

https://doi.org/10.1182/blood-2023-179551

Published: 2023

Journal Articles

Stromal Cell-Derived Factor 1 Alpha (SDF-1α), Cartilage Oligomeric Matrix Protein (COMP) and Circulating microRNAs 208a-3p and 221-3p: Potential Signature Biomarkers of Hemophilic Arthropathy

Alexandre Leuci, Melanie Robert, Laurie Josset, Muriel Marano, Philippe Connes, Stephanie Desage, Sandrine Meunier, Anne Lienhart, Yesim G. Dargaud

Blood (2023) 142 (Supplement 1): 5467.

https://doi.org/10.1182/blood-2023-179574

Published: 2023

Journal Articles

Individually Tailored By-Passing Therapy for the Management of Breakthrough Bleeds in Hemophilia Patients with Inhibitors Receiving Prophylaxis with Emicizumab

Yesim Dargaud, MD PhD, Anne Lienhart, MD, Nathalie Enjolras, PhD, Claude Negrier, MD

Blood (2017) 130 (Supplement 1): 3675.

https://doi.org/10.1182/blood.V130.Suppl_1.3675.3675

Published: 2017

Journal Articles

Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

Claude Negrier, MD, Lynda Mae Lepatan, MD, Faralzah Karim, MD, Anne Lienhart, MD, Denise Wolko, Christine Voigt, PhD, Iris C. Jacobs, MD, Elena Santagostino, MD PhD

Blood (2015) 126 (23): 2298.

https://doi.org/10.1182/blood.V126.23.2298.2298

Published: 2015

Journal Articles

Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery

Yesim Dargaud, Anne Lienhart, Claude Negrier

Blood (2010) 116 (25): 5734–5737.

https://doi.org/10.1182/blood-2010-06-291906

Published: 2010

NARROW

Multicenter Evaluation of the Hemostatic Activity of Emicizumab in Patients with Severe Hemophilia a Using Thrombin Generation Assay

Stromal Cell-Derived Factor 1 Alpha (SDF-1α), Cartilage Oligomeric Matrix Protein (COMP) and Circulating microRNAs 208a-3p and 221-3p: Potential Signature Biomarkers of Hemophilic Arthropathy

Individually Tailored By-Passing Therapy for the Management of Breakthrough Bleeds in Hemophilia Patients with Inhibitors Receiving Prophylaxis with Emicizumab

Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery

Email alerts

ASH Publications

American Society of Hematology

Multicenter Evaluation of the Hemostatic Activity of Emicizumab in Patients with Severe Hemophilia a Using Thrombin Generation Assay

Stromal Cell-Derived Factor 1 Alpha (SDF-1α), Cartilage Oligomeric Matrix Protein (COMP) and Circulating microRNAs 208a-3p and 221-3p: Potential Signature Biomarkers of Hemophilic Arthropathy

Individually Tailored By-Passing Therapy for the Management of Breakthrough Bleeds in Hemophilia Patients with Inhibitors Receiving Prophylaxis with Emicizumab

Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only